<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01670513</url>
  </required_header>
  <id_info>
    <org_study_id>DPSI-IDP-118-P2-01</org_study_id>
    <nct_id>NCT01670513</nct_id>
  </id_info>
  <brief_title>A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118</brief_title>
  <acronym>IDP-118</acronym>
  <official_title>A Phase 2 Dose Ranging, Evaluator-Blinded Study to Evaluate the Safety of Topical IDP-118</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dow Pharmaceutical Sciences</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dow Pharmaceutical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Subjects with a clinical diagnosis of plaque psoriasis with 10% to 20% of body surface area
      affected will be enrolled in the study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Approximately 60 subjects with a clinical diagnosis of moderate or severe psoriasis (defined
      as at least of 10 % - 20% treatable Body Surface Area (BSA) and an Investigator's Global
      Evaluation (IGE) of 3 or 4 at baseline (moderate or severe) will be enrolled in the study.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>June 2012</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">May 2013</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of HPA axis suppression after treatment with investigational drug product and the comparators</measure>
    <time_frame>8 weeks</time_frame>
    <description>To measure the incidence of HPA axis suppression after treatment with investigational drug product and the comparators</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety and cutaneous tolerability of the two formulations and the comparators</measure>
    <time_frame>8 weeks</time_frame>
    <description>To evaluate and Local Skin Reactions: Tolerability will be evaluated through assessment of selected local signs and symptoms at the drug-application site: itching, dryness, burning and stinging. In addition the treatment areas will be examined at each visit for significant known drug-related AEs such as skin atrophy, striae, telangiectasia and folliculitis.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>To evaluate efficacy, defined as reduction of severity of disease in a sample target plaque during the course of the study</measure>
    <time_frame>8 weeks</time_frame>
    <description>The Investigator will assess the target lesion site affected by psoriasis at each visit. Areas affected by psoriasis (at a minimum 10% BSA) are to be treated with study drug</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>IDP-118 Low Strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDP-118 Low Strength</description>
  </arm_group>
  <arm_group>
    <arm_group_label>IDP-118 High Strength</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>IDP-118 High Strength</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-118 Low Strength</intervention_name>
    <description>8 weeks</description>
    <arm_group_label>IDP-118 Low Strength</arm_group_label>
    <other_name>IDP-118</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IDP-118 High Strength</intervention_name>
    <description>8 weeks</description>
    <arm_group_label>IDP-118 High Strength</arm_group_label>
    <other_name>IDP-118</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female of any race, 18 to 65 (inclusive) years of age.

          -  Freely given verbal and written informed consent obtained from the subject.

          -  Clinical diagnosis of psoriasis at the Screening and Baseline visits with

          -  At least 10% - 20% of total treatable BSA involvement, and

          -  an Investigator's Global Evaluation score of 3 or 4 ( moderate or severe) on a scale
             of 0 to 5

          -  Good general health as determined by the Investigator based on the subject's medical
             history and physical examination, with Screening hematology, serum chemistry, and
             urinalysis laboratory values within normal range limits.

        Exclusion Criteria:

          -  Presence of psoriasis that was previously treated with prescription medication prior
             to the Screening visit and is non-responsive to corticosteroid treatment, as
             determined by the Investigator.

          -  Presence of any concurrent skin condition that could interfere with the evaluation of
             the study drug, as determined by the Investigator.

          -  History of adrenal disease

          -  Female who is pregnant, nursing an infant, or planning a pregnancy during the study
             period.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Todd Plott, MD</last_name>
    <role>Study Director</role>
    <affiliation>Medical Monitor</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dow Clinical Study Site</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dow Clinical Study Site</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dow Cliincal Study Site</name>
      <address>
        <city>Fort Gratiot</city>
        <state>Michigan</state>
        <zip>48059</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dow Clinical Study Site</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dow Clinical Study Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dow Clinical Study Site</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 31, 2012</study_first_submitted>
  <study_first_submitted_qc>August 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 22, 2012</study_first_posted>
  <last_update_submitted>April 23, 2013</last_update_submitted>
  <last_update_submitted_qc>April 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

